HLS Therapeutics Inc.
HLS
Classificação em ações
#21879
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Preço da ação
$3.05
Valor de mercado
$94.22M
Variação (1 dia)
1.47%
Variação (1 ano)
-24.23%
País
CA
Negociar HLS Therapeutics Inc. (HLS)
Categoria
Healthcare
Rácio P/B de HLS Therapeutics Inc. (HLS)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da HLS Therapeutics Inc., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da HLS Therapeutics Inc. de 2026 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | - |
IN
|
